Alkem Laboratories Limited Latest Updates

$ALKEM Upcoming Q1 FY27 Financial Results Schedule Alkem Laboratories has officially notified stock exchanges that its Board of Directors is scheduled to meet on Friday, August 14, 2026, to review and approve the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026 (Q1 FY27). The company will host its post-earnings management conference call on the same date. Final Dividend Record Date & AGM The Board recommended a final dividend of ₹10.00 per equity share (face value ₹2) for FY25–26. The company established Friday, August 7, 2026, as the record date to determine shareholder entitlement, with final disbursement scheduled for September 26, 2026, subject to shareholder approval at its Annual General Meeting on August 27, 2026. FY26 Annual Financial Summary For the full financial year 2025–26, Alkem reported a 14% year-on-year increase in consolidated revenue from operations to ₹14,710 crore. Consolidated net profit (PAT) expanded 6.3% YoY to ₹2,300 crore (EPS of ₹193), with steady volume growth across its domestic branded formulations portfolio offsetting trade generic restructuring adjustments. Senior Leadership Resignation In corporate governance filings, the company disclosed that Dr. Jitendra Singh Huda, a Senior Management Personnel, tendered his resignation to pursue external opportunities, effective July 23, 2026. This follows the earlier planned executive transition of Chief Executive Officer Dr. Vikas Gupta, who stepped down on June 30, 2026. Patent Litigation Settlement with Esperion Alkem executed a settlement agreement with Esperion Therapeutics regarding patent litigation over generic versions of NEXLETOL (Bempedoic Acid) and NEXLIZET (Bempedoic Acid & Ezetimibe). Under the terms, Alkem is permitted to launch its generic versions in the United States on or after April 19, 2040, resolving pending U.S. ANDA disputes.